Core Viewpoint - The company, Guangzhou Maipu Regenerative Medicine Technology Co., Ltd., is adjusting its plan for issuing shares and cash payment to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd., including changes to the subscription targets, pricing benchmark date, and issuance price for the fundraising [2][3]. Group 1: Adjustments to Fundraising Plan - The original subscription target for the fundraising was the actual controller Yuan Yuyu, but it has been adjusted to Guangzhou Yijian Medical Investment Co., Ltd., which is 100% owned by Yuan Yuyu [3][4]. - The pricing benchmark date for the fundraising has been changed to the date of the announcement of the resolution from the 12th meeting of the third board of directors [3][4]. - The new issuance price for the fundraising is set at 57.35 yuan per share, which is not less than 80% of the average stock price over the 20 trading days prior to the pricing benchmark date [4][5]. Group 2: Meeting Resolutions and Approvals - The adjustments to the fundraising plan were approved during the 12th meeting of the third board of directors held on August 11, 2025, which included the review of the related party transaction [5]. - Independent directors conducted a special meeting to review and express agreement with the adjustments made to the fundraising plan [4][5]. - The company ensures that the adjustments do not harm the interests of the company or minority shareholders [3][4].
迈普医学: 关于发行股份及支付现金购买资产并募集配套资金暨关联交易调整募集配套资金认购对象、募集配套资金定价基准日及发行价格并修订预案的公告